News | Heart Valve Technology | September 22, 2016

4Tech Reports First Successful Implant of TriCinch Transcatheter Tricuspid Valve Repair Device

World’s first TTVR procedure without use of TEE or general anesthesia successful for high-risk surgical patient

4Tech, TriCinch TTVR, transcather tricuspid valve repair device, first implant

September 22, 2016 — 4Tech Inc. announced that its TriCinch device has been used in the world’s first-ever successful transcatheter tricuspid valve repair without the use of transesophageal echocardiography (TEE) or general anesthesia to successfully treat tricuspid regurgitation (TR). The TriCinch implant took less than one hour and allowed substantial reduction of TR.

The ongoing feasibility study is being conducted at San Raffaele Hospital and in other sites in Italy and in Europe. Investigators for the study include Azeem Latib, M.D., senior interventional cardiologist; Eustachio Agricola, M.D., senior echocardiographist; and Paolo Denti, M.D., hybrid cardiovascular surgeon.

“Our patient was at very high risk for surgical treatment, and she was referred to us by a cardiac surgeon,” said Agricola. “Equally critical, she was unable to undergo TEE because of an esophageal diverticulum and thus there were extremely limited options for offering her any treatment.”

“Fortunately, the extensive experience of the San Raffaele team with transcatheter treatment of the tricuspid valve and cardiac imaging allowed for the treatment,” added Latib. “The successful treatment of this case opens up new options for minimally invasive treatment of patients with FTR (functional tricuspid regurgitation).”

TR is a difficult-to-manage, age-related disease in which blood “backflows” into the right side of the heart. Today’s standard of care for TR is medical management. Surgical intervention is very high-risk. In-hospital death post-cardiac surgery for isolated TR can be as high as 37 percent. Unfortunately, TR patients tend to be non-compliant with their medications. Thus, TR and related complications induce substantial healthcare spending due to frequent re-hospitalizations. Furthermore, TR leads to chronic renal failure and end-stage dialysis. The combination of these negative outcomes results in a significant unmet need for an interventional cardiology solution to TR.

The 4Tech TriCinch System for Transcatheter Tricuspid Valve Repair is in the early phase of development. It will not be available in the United States for clinical trials until further notice and is not available for sale.

Watch the VIDEO "Transcatheter Tricuspid Valve Repair and Replacement Technologies," and discussion with Rebecca Hahn, M.D.

For more information: www.4techtricuspid.com


Related Content

News | Heart Valve Technology

June 27, 2025 – Foldax Inc., a leader in the development of innovative polymer heart valves, has announced compelling ...

Home June 27, 2025
Home
News | Heart Valve Technology

June 04, 2025 — HeartSciences Inc. has announced that the U.S. Food and Drug Administration has granted Breakthrough ...

Home June 12, 2025
Home
News | Heart Valve Technology

May 27, 2025 — Abbott has announced the U.S. Food and Drug Administration (FDA) has approved the company's Tendyne ...

Home May 28, 2025
Home
News | Heart Valve Technology

May 2, 2025 – New analysis from the EARLY TAVR trial showed patients between the age of 65 and 70 years old derived the ...

Home May 02, 2025
Home
News | Heart Valve Technology

April 28, 2025 — The Society of Thoracic Surgeons (STS) has launched its latest surgical risk calculator designed for ...

Home April 29, 2025
Home
News | Heart Valve Technology

March 30, 2025 — Medtronic has announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data ...

Home March 31, 2025
Home
News | Heart Valve Technology

Feb. 22, 2025 — More than 60,000 people die from heart valve disease (HVD) in the U.S. each year, according to the ...

Home March 04, 2025
Home
News | Heart Valve Technology

Feb. 17, 2025 — The International Consortium for Health Outcomes Measurement (ICHOM) has developed a globally inclusive ...

Home February 18, 2025
Home
News | Heart Valve Technology

Feb. 13, 2025 — Research from Cedars-Sinai investigators and collaborators at other leading medical institutions is ...

Home February 18, 2025
Home
News | Heart Valve Technology

Jan. 25, 2025—A new study presented at the 2025 Society of Thoracic Surgeons (STS) Annual Meeting reveals that ...

Home January 27, 2025
Home
Subscribe Now